share_log

Earnings Call Summary | PaySign(PAYS.US) Q1 2024 Earnings Conference

Earnings Call Summary | PaySign(PAYS.US) Q1 2024 Earnings Conference

業績電話會議摘要 | PaySign (PAYS.US) 2024 年第一季度業績會議
富途資訊 ·  05/12 06:29  · 電話會議

The following is a summary of the Paysign, Inc. (PAYS) Q1 2024 Earnings Call Transcript:

以下是Paysign, Inc.(PAYS)2024年第一季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Paysign reported Q1 2024 revenue of $13.2 million, marking a 30% increase year-over-year.

  • Paysign's adjusted EBITDA increased by 135% to $1.7 million, or $0.03 per fully diluted share, up from $720,000 in the previous year.

  • Gross dollar load volume and gross spend volume rose by 13% and 11% respectively.

  • The Patient Affordability business contributed to 59% of the total year-over-year revenue growth with a 305% increase in revenue.

  • Paysign報告稱,2024年第一季度收入爲1,320萬美元,同比增長30%。

  • Paysign調整後的息稅折舊攤銷前利潤從去年的72萬美元增長了135%,至170萬美元,攤薄後每股收益爲0.03美元。

  • 美元總負荷量和總支出量分別增長了13%和11%。

  • 患者負擔能力業務貢獻了總收入同比增長的59%,收入增長了305%。

Business Progress:

業務進展:

  • Paysign expanded its patient affordability programs to reach a total of 53 active programs.

  • An entrance into retail drug programs with 4 programs added in Q1 and more expected to launch in the future.

  • The plasma donor compensation business saw an 11% increase in revenue.

  • The company anticipates adding 15 to 25 new plasma donor centers in 2024.

  • Paysign is seeking to enter new markets while also investing in its personnel and systems to meet growing demand.

  • Paysign將其患者負擔能力計劃擴展到總共53個活躍計劃。

  • 零售藥品計劃的入口,第一季度增加了4個項目,預計將來還會推出更多項目。

  • 血漿捐贈者補償業務的收入增長了11%。

  • 該公司預計,2024年將增加15至25個新的血漿捐贈中心。

  • Paysign正在尋求進入新市場,同時還投資其人員和系統,以滿足不斷增長的需求。

More details: PaySign IR

更多詳情: PaySign IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論